Sophia Wong

⭐️Great first session on #AdoptiveCellTherapy chaired by Samra Turajlic

Starting w/ @haanenjohn.bsky.social
on #TIL #TCR, Sonia Guedan on #CART & Jeff Miller on #NKTherapy

Academic manufacturing is possible! We need to work w/ industry/regulators to move closer to #cure 🔥

#ESMO25

Great talk by Sebastian Klobuch @sklobuch.bsky.social from @nkinl.bsky.social on #CellTherapy - so much still to learn and grow in this space 🙌🏼

@myesmo.bsky.social #ESMO25

Pre-Cancer Immunology The Pre-Cancer Immunology Lab (James Reading Lab) is mapping pre-invasive T cell dynamics during carcinogenesis to detect and intercept cancer development.

🚨 PhD Position available in our lab 🚨 exploring the power of blood immune multi-omics to detect lung cancer years prior to clinical diagnosis in a unique cohort of >10,000 CT screened individuals.
✅ Wet & dry lab
✅ September 2025 enrolment
✅ UK tuition fees only

www.ucl.ac.uk/medical-scie...

Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial - Nature Medicine In an iterative phase 2 trial, patients with metastatic, treatment-refractory, mismatch repair proficient gastrointestinal cancers had responses to neoantigen-reactive tumor-infiltrating lymphocytes b...

Congrats to Dr Steve Rosenberg & team for another outstanding study👏🏼
✅Neoantigen reactive #TIL in #MMR proficient #GI cancers has sustained responses
✅Adding pembro increases responses
❗️Median time to Tx is 3-4m; more efforts needed to increase availability in our pts
www.nature.com/articles/s41...

Thank you @keystonesymposia.bsky.social for a wondering meeting. Lots of #immunology #celltherapy 💉🦠discussed! Now to get back to fun and exciting work back home 🇸🇬!

Of course! Picture of @SunshineVillage ! #skiing ⛷️and #work combo is the best! 😍 Till next time! ❤️

Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial Nature Medicine - In this phase 1 trial of a personalized, neoantigen-specific autologous T cell therapy, BNT221, when given as monotherapy in patients with metastatic melanoma refractory to PD-1...

Just published: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
rdcu.be/d5ptS

Do check out our review on #celltherapy toxicities in solid cancers out now on #ESMO IO tech!

Breaking the mold: Unconventional T cells in cancer therapy Unconventional T cells, including invariant natural killer T (iNKT) cells, gamma delta (γδ) T cells, and mucosal-associated invariant T (MAIT) cells, play important roles in both innate and adaptive immunity. These cells respond to tumors rapidly and influence the tumor microenvironment (TME). Recent advances in understanding their biology, as well as the development of novel therapeutic approaches, have underscored their potential in cancer immunotherapy. This commentary will assess these advances and translational possibilities in the field.

Awesome review on unconventional T cells! Breaking the mold in cancer therapy #CancerCell www.cell.com/cancer-cell/...

Also check out @DrGopalIyer recent review on GD on #ESMO #IOTech
A GD Type of Cancel Culture - www.esmoiotech.org/article/S259...

#CellTherapy
#GammaDelta
#NKT

😂 too flattering! Can’t do it without global collaboration and networking like yourself, @drjonlim.bsky.social and many others! Do keep me posted on your endeavours both of you! I’m watching from SG! 🤩🤩🤩

Congrats @zaydtippu.bsky.social 👏🏼👏🏼👏🏼

Dr Allison Betof Warner @DrBetofMDPHD #Stanford talks #TIL / this post mostly showing #melanoma #Brain #metastases TIL plus future steps /
#Bridge2024 #FinishCancer @melanomaau.bsky.social @melanomaresearch.bsky.social @impactmelanoma.bsky.social #MRF @sitcancer.bsky.social

Let’s go! 🙌🏼🙌🏼🙌🏼
#CellTherapy
#TILTherapy

Welcome to 🦋🦋🦋
@drbetofmdphd.bsky.social
@sklobuch.bsky.social

What an honour hosting John Haanen #nki today #NCCS - talking all #celltherapy #TILtherapy & visiting our national GMP facility 👩🏻‍🔬

And a fascinating talk on myeloids in lung by @charlesswanton.bsky.social ☺️

#ESMOAsia24

Looking forward to this debate tomorrow here in National Cancer #Singapore with a ⭐️ star-studded line up! 🔥 Register below and see you tomorrow!

#CancerImmunotherapy
#ESMOAsia
#NCCS

The changing treatment landscape of EGFR-mutant non-small-cell lung cancer - Nature Reviews Clinical Oncology Third-generation EGFR tyrosine-kinase inhibitors (TKIs) are the standard-of-care first-line treatment for patients with advanced-stage EGFR-mutant NSCLC and their efficacy is being investigated in ear...

Great review and overview of EGFR mutant NSCLC - 20 years since its discovery!

#EGFR
#NSCLC

www.nature.com/articles/s41...

Fascinating how this was 40 years ago! Truly inspiring and we will be delivering #celltherapy to our patients here in #Singapore too!
#TILTherapy
#cancerimmunotherapy

💥 #Cancer #Vaccines in combo IO are #HOT!! Wasn’t on Bsky 11/8 so posting now/@ #SITC2024 we reported tripling of response rate & progression-free survival #PFS in #HNSCC + COOL #TCR #LAG3 & #DarkMatter data @patrickhwumd.bsky.social @chrystalpaulos.bsky.social www.einpresswire.com/article/7584...

Awesome review on combination strategies with ICB #CancerImmunotherapy #ImmuneCheckpoint

Wonderful work @barralab.bsky.social on the role of NKT cells in gut epithelial cell homeostasis. Huge congrats to Patricia, the team and @martalebrusant.bsky.social a rising unconventional T cell superstar that we are lucky to have slaying it in our lab!

Great team and opportunity to work with! Do apply! 📝📝📝

Snapshot @Cell
Advances in cancer immunotherapies

Beyond the blood: expanding CAR T cell therapy to solid tumors - Nature Biotechnology Recent clinical trials testing CAR T cells on solid tumors have yielded promising outcomes that can be enhanced with further CAR engineering.

Beyond the blood: expanding CAR-T to solid tumors

www.nature.com/articles/s41...

Let’s go! 🦋

Sharing a fledgling #LCSM starter pack for those joining Bluesky 🦋

#Medsky #Oncsky @oncoalert.bsky.social

go.bsky.app/MjDxbG2

Joining the bandwagon on 🦋 @bsky.app

#FullyOnboard #NewBeginnings